Gamma-Carboline PTSD Treatment via 5-HT2 Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for posttraumatic stress disorder (PTSD) and impulse control disorder (ICD) such as intermittent explosive disorder (IED) have limited efficacy and low remission rates, particularly in severe cases, and there is a need for improved pharmacologic interventions.
Innovation Solution
Administration of specific substituted heterocycle fused gamma-carbolines, either alone or in combination with antidepressants, to treat agitation, aggressive behaviors, PTSD, and/or ICD, targeting 5-HT2 receptors and normalizing brain dopamine activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antidepressant treatments are used for PTSD and ICD, then treatment coverage is provided, but efficacy is limited and remission rates are low
Solution Approach 1:
The patent introduces a novel compound class (substituted heterocycle fused gamma-carbolines) with a different chemical structure and mechanism of action compared to traditional antidepressants. This represents a fundamental parameter change in the therapeutic approach, moving from conventional antidepressant mechanisms to 5-HT2A receptor antagonism, thereby improving efficacy for treatment-resistant PTSD and ICD cases
Solution Approach 2:
The patent segments the treatment approach by identifying and targeting specific receptor subtypes (5-HT2A receptors) rather than using broad-spectrum antidepressant mechanisms. This segmentation allows for more precise therapeutic action on the specific neural pathways involved in PTSD and ICD, improving treatment efficacy while reducing off-target effects
2Reliability
If new compound classes are introduced to improve PTSD and ICD treatment, then treatment effectiveness increases, but treatment complexity increases
Solution Approach 1:
The substituted heterocycle fused gamma-carboline compounds demonstrate multi-functionality by effectively treating multiple related conditions (PTSD and various impulse control disorders) through a single mechanism of action (5-HT2A receptor antagonism). This universal approach simplifies treatment planning and reduces the need for multiple different medications, thereby improving remission rates without proportionally increasing treatment complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The substituted heterocycle fused gamma-carbolines demonstrate effectiveness in treating PTSD and ICD, offering improved remission rates and complementary mechanisms with antidepressants, addressing symptoms such as depression, psychosis, and cognitive impairment.
Implementation Method 1
Administration of specific substituted heterocycle fused gamma-carbolines, either alone or as an adjunct to antidepressants, to treat agitation, aggressive behaviors, PTSD, and ICD, which act as agonists or antagonists of 5-HT2 receptors, modulating central nervous system activity
Data Source
AI summary
Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders.